Table 1

IC50s of a panel of topo I inhibitors in the IGROV1, T8, and MX3 cell lines with or without GF120918

Cytotoxicity was assessed using the SRB assay.
IGROV1 IC50 nmIGROV1 + GF120918 IC50 nmIC50 ratio ± GF120918
TPT8.978.861.01a
CPT-114855790.84a
SN-381.581.001.58a
9-AC1.802.090.86a
NX2110.730.930.78a
DX8951f0.090.130.70a
BNP13500.450.730.62a
T8 IC50 nmRfbT8 + GF120918 IC50 nmRfIC50 ratio ± GF120918
TPT1,00011137.44.227c
CPT-1132,260672,8604.911c
SN-384102595.785.871c
9-AC1789912.35.914c
NX21123.1324.254.65.4c
DX8951f2.52270.372.76.8c
BNP13504.42102.833.91.6a
MX3 IC50 nmRfMX3 + GF120918 IC50 nmRfIC50 ratio ± GF120918
TPT2733013.41.520c
CPT-1112,450261,0301.812c
SN-3885.5540.920.993c
9-AC23.4134.672.25.0c
NX21110.7152.492.74.3c
DX8951f0.384.00.141.02.7a
BNP13500.932.11.381.90.7a
  • a No significant difference ± GF120918 (P > 0.05).

  • b IC50 (T8 or MX3):IC50 IGROV1.

  • c Significant difference ± GF120918 (P < 0.05).